Reviva Reports Third Quarter 2024 Financial Results And Recent Business Highlights
(MENAFN- GlobeNewsWire - Nasdaq) – 108 patients have completed 1-year of treatment in 1-year open-label extension (OLE) trial – – Vocal biomarker speech latency data from RECOVER trial reinforce brilaroxazine's improvement on negative symptoms and …